Clinical experience in the treatment of COVID-19 with monoclonal antibodies in solid organ transplant recipients DOI Creative Commons
Elena Múñez, Jorge Calderón‐Parra,

Andrea Gutiérrez‐Villanueva

et al.

Revista Española de Quimioterapia, Journal Year: 2023, Volume and Issue: 36(Suppl1), P. 25 - 28

Published: Nov. 24, 2023

Solid organ transplant (SOT) recipients are at high risk for complications from coronavirus disease 2019 (COVID-19). SOT mount lower immunological responses to vaccines than general population and breakthrough COVID-19 infections. Passive immunotherapy in the form of anti-Spike monoclonal antibodies (MoAbs) may be an alternative prophylaxis treatment these patients. SARS-CoV-2 has evolved by accumulating resistance mutations that have escaped neutralizing action most MoAbs. However, MoAbs directed more conserved epitopes maintain effector functions could efficacy According published data, with low anti-spike antibody vaccination benefit use pre-exposure prophylaxis, mild moderate severe less 15 days symptom duration oxygen requirements. Combination therapy effective monotherapy mild-to-moderate infection.

Language: Английский

Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: A prospective cohort study DOI Creative Commons
Jorge Calderón‐Parra, Andrea Gutiérrez-Villanueva, Gerard Ronda-Roca

et al.

International Journal of Antimicrobial Agents, Journal Year: 2024, Volume and Issue: 63(3), P. 107095 - 107095

Published: Jan. 21, 2024

Antivirals and monoclonal antibodies are available to lower progression risk in immunocompromised patients. However, combination therapy with both types of agents has not been studied. Single-centre prospective cohort study. We enrolled all patients who received treatment for mild-to-moderate COVID-19 from January 1st, 2022, October 30th, 2022. Primary endpoint was at 90 days, defined as hospital admission or death due and/or seronegative persistent Three hundred four (304) were included. 43 (14.1%) sotrovimab plus a direct-acting antiviral 261 (85.9%) monotherapy. outcome occurred more frequently after monotherapy (4.6% vs 0%, p=0.154). Among anti-Spike IgG titter below 750 BAU/mL, frequent (23.9% p=0.001), including COVID-related (15.2% p=0.014) (10.9% p=0.044). Combination associated (OR 0.08, 95% CI 0.01-0.64). Anti-S than BAU/mL previous antiCD20 higher 13.70, 2.77-67.68; OR 3.05, 1.20-10.94, respectively). In immunocompromised, an may be effective SARS-CoV2.

Language: Английский

Citations

9
Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations DOI Creative Commons
Juthaporn Cowan, Ashley Amson, Anna Christofides

et al.

International Journal of Infectious Diseases, Journal Year: 2023, Volume and Issue: 134, P. 228 - 238

Published: July 1, 2023

The objective of this review was to examine the latest literature regarding effectiveness monoclonal antibodies as COVID-19 prophylaxis therapy for immunocompromised patient populations.Literature published real-world and randomized control trials (RCTs) from 2020 May 2023.COVID-19 is highly transmissible with potentially serious health outcomes, underscoring need effective prevention treatment strategies. Vaccines are at preventing general population; however, efficacy often impaired in patients given insufficient response initial exposure and/or memory secondary exposures. Some individuals may also have contraindications vaccination. As such, additional protective measures needed bolster immune these populations. Monoclonal been bolstering system responses among patients; they proving ineffective against most recent Omicron strains (BA.4 BA.5).Several studies investigated pre- post-prophylaxis COVID-19. Historical evidence promising; new variants concern challenging currently available regimens.

Language: Английский

Citations

16
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C) DOI Creative Commons
Christopher F. Bell, Priyanka Bobbili, Raj Desai

et al.

Clinical Drug Investigation, Journal Year: 2024, Volume and Issue: 44(3), P. 183 - 198

Published: Feb. 20, 2024

The coronavirus disease 2019 (COVID-19) pandemic has been an unprecedented healthcare crisis, one that threatened to overwhelm health systems and prompted urgent need for early treatment options patients with mild-to-moderate COVID-19 at high risk progression severe disease. Randomised clinical trials established the safety efficacy of monoclonal antibodies (mAbs) in pandemic; vitro data subsequently led use mAbs being discontinued, without clear evidence on how these were linked outcomes. In this study, we describe compare real-world outcomes treated sotrovimab versus untreated patients.

Language: Английский

Citations

1
Resistance Analysis Following Sotrovimab Treatment in Participants with COVID-19 During the Phase III COMET-ICE Study DOI Creative Commons

Sambhavi Subramanian,

Gretja Schnell,

Julia di Iulio

et al.

Future Virology, Journal Year: 2023, Volume and Issue: 18(15), P. 975 - 990

Published: Oct. 1, 2023

Aim: Sotrovimab is an engineered human monoclonal antibody that binds a conserved region of the SARS-CoV-2 spike protein. The COMET-ICE phase III study evaluated sotrovimab for treatment mild to moderate COVID-19 in nonhospitalized participants with ≥1 risk factor severe disease progression. Materials & methods: We presence circulating variants concern or interest (VOCs/VOIs) and characterized baseline, post-baseline emergent amino acid substitutions detected epitope SARS-CoV-2. Results: None sotrovimab-treated baseline substitutions, 1 48 met primary clinical endpoint Conclusion: Overall, progression was not associated identified VOC/VOI participants.

Language: Английский

Citations

3
Sotrovimab in Severe COVID-19 anti-S Seronegative Immunocompromised Patients: Multicenter Retrospective Cohort DOI Creative Commons

Rubén Lobato-Cano,

Alberto Romero-Palacios,

Laurine Prinet

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: June 6, 2024

Abstract Purpose: Sotrovimab’s effectiveness remains uncertain in severely immunocompromised inpatients with COVID-19, particularly amidst the emergence of Omicron subvariants. Our study aimed to evaluate clinical progress and safety severe COVID-19 at-risk treated sotrovimab. Methods: Retrospective multicentric cohort (four teaching hospitals from Andalusian Health System) that included adult inmunosupression negative anti-S serology who received sotrovimab December 2021 March 2023. Primary outcomes focused on respiratory progression (High-flow oxygen/Invasive Non-invasive support mortality at 28-day) while secondary variables encompassed hospital stay duration readmission reasons. Results: 79 patients were included, 58.2% male, a median age 72 years (P25-P75 65-79). Significant immunosuppression factors hematologic neoplasms 51.9% patients, solid organ transplants 17.7%, 13.9% systemic autoimmune diseases. The interval between symptom onset infusion was 12 days (P25-P75 8-22), 13 13-26). 36.7% deceased, 32.9% attributed directly COVID-19. No adverse reactions reported. Univariate analysis linked severity admission (p<0.05). Patients distributed among dominant subvariants across five periods: BA.1 (15%), BA.2 (25%), BA.3 (31.3%), BQ.1 (16.3%), XBB.1.5 (11.4%). Conclusions The underscores need for further investigations establish sotrovimab's efficacy cases immunocompromise. Early treatment initiation may be crucial considering potential limitations its use advanced forms.

Language: Английский

Citations

0
Clinical practice guideline supported administration of monoclonal antibody therapy for high-risk patients with COVID-19: Experience of a quaternary care centre DOI
Keely Hammond,

François Bourdeau,

Marina Klein

et al.

Journal of the Association of Medical Microbiology and Infectious Disease Canada, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 3, 2024

Background: Immunocompromised patients remain at risk of progression to severe COVID-19 disease. Methods: We describe clinical COVID-19-related outcomes after administration anti-SARS-CoV-2 monoclonal antibodies (mAb) following institutional practice guidelines (CPGs) in 205 high-risk between November 2021 and April 2022 a Canadian quaternary care centre. Results: Median patient age was 59 years; 102 (50%) were female. Eighty-two (40%) transplant recipients, 47 (23%) had hematologic malignancies, 25 (12%) solid organ 51 (25%) another indication. Forty-eight received fewer than two doses vaccines. The majority (80%) mild disease presentation with 14% moderate 6% severe. time from symptom onset mAb 3 days (IQR 2.0-5.5 days). Of those who as outpatients, 90 (93%) favourable (no hospitalizations or death within months). inpatients, 93 (86%) (discharged without re-admission death), 4% re-admitted, 10% died. In logistic regression analysis, only severity associated unfavourable outcomes. Fewer vaccine not outcomes, suggesting potential benefit among the under-vaccinated. There significant difference adherence CPGs outpatients versus inpatients (adherent for 85% 58%, p<0.001), where non-adherence occurred cases Conclusion: CPG-supported management may be useful model guide future therapies.

Language: Английский

Citations

0
Host-Directed Adjunctive Therapies in Immunocompromised Patients with Pneumonia DOI
Matthew K. Hensley, Charles S. Dela Cruz

Clinics in Chest Medicine, Journal Year: 2024, Volume and Issue: 46(1), P. 37 - 48

Published: Dec. 9, 2024

Language: Английский

Citations

0
Clinical experience in the treatment of COVID-19 with monoclonal antibodies in solid organ transplant recipients DOI Creative Commons
Elena Múñez, Jorge Calderón‐Parra,

Andrea Gutiérrez‐Villanueva

et al.

Revista Española de Quimioterapia, Journal Year: 2023, Volume and Issue: 36(Suppl1), P. 25 - 28

Published: Nov. 24, 2023

Solid organ transplant (SOT) recipients are at high risk for complications from coronavirus disease 2019 (COVID-19). SOT mount lower immunological responses to vaccines than general population and breakthrough COVID-19 infections. Passive immunotherapy in the form of anti-Spike monoclonal antibodies (MoAbs) may be an alternative prophylaxis treatment these patients. SARS-CoV-2 has evolved by accumulating resistance mutations that have escaped neutralizing action most MoAbs. However, MoAbs directed more conserved epitopes maintain effector functions could efficacy According published data, with low anti-spike antibody vaccination benefit use pre-exposure prophylaxis, mild moderate severe less 15 days symptom duration oxygen requirements. Combination therapy effective monotherapy mild-to-moderate infection.

Language: Английский

Citations

0